Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novel treatment options for metabolic disorders claimed in recent patents

Aug. 29, 2008

Ark commences patient enrollment in phase III Vitor pilot study in cachexia

Aug. 27, 2008

Recent patents report novel treatment options for endocrine disorders

Aug. 27, 2008

Oxygen Biotherapeutics to meet with FDA for proposed phase IIb Oxycyte trial

Aug. 26, 2008

Generex signs oral insulin distribution deal with Dong-Sung for Korea

Aug. 26, 2008

Novel treatment options for anemia described in recent GSK patent

Aug. 26, 2008

AT1-AAs implicated in pre-eclampsia in mouse studies

Aug. 26, 2008

FDA approves Nplate for adult chronic immune thrombocytopenic purpura

Aug. 25, 2008

New glucocorticoid receptor modulator identified at GSK

Aug. 25, 2008

Ardea Biosciences commences phase I trials for gout candidate RDEA-594

Aug. 22, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...